Microbial Diversity of Pancreatic Diseases

Launched by RUIJIN HOSPITAL · Jan 16, 2019

Keywords

ClinConnect Summary

This clinical trial is investigating the types of bacteria and other microorganisms living in the digestive system of patients with pancreatic cancer, as well as those with other pancreatic diseases and healthy individuals. By comparing these different groups, the researchers hope to understand how the microbial community varies and to identify potential markers that could help in diagnosing or treating pancreatic diseases.

To participate in this study, individuals need to be between 3 and 85 years old and must have a confirmed diagnosis of pancreatic cancer or another pancreatic disease following surgery or a specific procedure called ERCP. They should not have serious issues with their heart, liver, or kidneys. Participants can expect to provide samples for analysis and be part of a larger effort to understand pancreatic diseases better. It's important to note that certain individuals, such as those with severe infections or a history of other cancers, cannot take part in this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 3 years old, ≤ 85 years old;
• • After MDT discussion, routine surgery or ERCP can be performed, and the postoperative pathology is clear as pancreatic cancer and other pancreatic diseases;
• • There is no serious damage to heart, liver and kidney function;
• Exclusion Criteria:
• • Women who are breast-feeding during pregnancy and after pregnancy;
• • Patients with evidence of sensory or motor neuropathy;
• • Those who have a clear cardiovascular disease, severe associated disease or active infection, including known HIV infection;
• • Those who have a history of other cancers;
• • Those who are allergic to drugs or their excipients